Omeros receives support for clinical study from National Institute on Drug Abuse

Omeros Corporation, a Seattle-based clinical-stage biopharmaceutical company, announced that “the National Institute on Drug Abuse (NIDA) is providing support for the Company’s Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute researchers.”

Read more in a press release from Omeros

Omeros is a WTC client

This entry was posted in 43rd_district, Company_and_Client_News, Funding, Life_Sciences, Omeros, RTD, Seattle. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s